NICE thumbs up for BMS leukaemia treatment
November 18, 2016Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, NICE, Sprycel, chronic myeloid leukaemia
Bristol-Myers Squibb has announced that NICE have given a Final Appraisal Determination recommending Sprycel (dasatinib) for the treatment of chronic …
New healthcare app aims to improve patient adherence
November 17, 2016Medical Communications, Sales and Marketing Echo, app, patient adherence, smartphone
The newly released app, named Echo, was developed by former Apple executive Dr Sai Lakshmi and former LloydsPharmacy executive Stephen …
Japan to slash Opdivo costs by 50%
November 17, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Japan, opdivo
Japan’s health ministry has announced it is to slash the price of Bristol-Myers Squibb’s Opdivo by 50% in the country …
Amgen boosted in race to market for migraine drug
November 17, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, Novartis, erenumab, migraine, phase III
Amgen released positive results from their second Phase III trial for experimental migraine drug, known as erenumab, which it is …
NICE rules Shire’s Onivyde not cost effective
November 17, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NHS, NICE, Onivyde, Shire
Shire’s Onivyde has been determined by NICE as not cost effective, in draft guidance, despite adding on average two months …
NICE approves Roche’s Perjeta for breast cancer
November 16, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NICE, Perjeta, Roche, breast cancer
NICE has announced its approval of Roche’s Perjeta (pertuzumab) as a neoadjuvant treatment of HER2-positive, locally advanced, inflammatory or early-stage …
Myelofibrosis market to increase to be worth over $1 billion by 2025
November 16, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EU, US, myelofibrosis
The myelofibrosis market is expected to grow from $545.2 million in 2015 to $1.02 billion by 2025, almost doubling in …
Surprising number of parents agree to use of placebos in children
November 16, 2016Medical Communications, Research and Development Placebo, children
A study by Boston Children’s Hospital found that parents recognised that placebos are a vital part of research and that …
Real world evidence: a reality check for pharma?
November 16, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing real world evidence
Rising demands on the industry has pharma firms calling for a more-effective, fit-for-purpose methodology for generating clinical data. Could the …
Powerful new data for MSD’s bladder cancer drug stops trial early
November 16, 2016Research and Development MSD, pembrolizumab
MSD has released new data which reinforces the efficacy of its anti-PD-1 therapy pembrolizumab in patients with advanced urothelial (bladder) …
Abbott-St. Jude $25 billion deal close to clearance
November 16, 2016Research and Development, Sales and Marketing Abbott, St. Jude, acquisition
EU antitrust regulators are due to reach a decision on the deal on 23 November that would see Abbott Laboratories …
Janssen’s Crohn’s treatment licensed for UK use
November 16, 2016Research and Development, Sales and Marketing Chrohn's disease, J&J, JJ, Janssen, Johnson & Johnson, Stelara
Janssen, a subsidiary of Johnson & Johnson, has announced that its treatment Stelara (ustekinumab) is now licensed by the European …
NICE rejects Celegene’s Revlimid as second-line treatment
November 16, 2016Research and Development, Sales and Marketing Celegene, Revlimid
NICE has decided Celegene’s multiple myeloma growth engine Revlimid (lenalidomide) will not be offered to patients as a second line …
New CMO and Executive Management Team member for Nordic Nanovector
November 15, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Nordic Nanovector has recruited a new chief medical officer (CMO) and Executive Management Team member with the appointment of Dr …
Novartis reportedly in talks to acquire Amneal in $8 billion deal
November 15, 2016Manufacturing and Production, Sales and Marketing Amneal pharmaceuticals, Novartis, joe jimenez
Novartis are said to be eyeing a deal for Amneal pharmaceuticals in order to bolster its Sandoz generics business. Bloomsberg …
Celgene’s Otezla hits primary endpoint in psoriatic arthritis study
November 15, 2016Manufacturing and Production, Research and Development Celgene, otezla, psoriatic arthritis
Celgene has unveiled new data on its selective inhibitor of phosphodiesterase 4 (PDE4) Otezla (apremilast) which shows that the treatment …
AbbVie investigational hep C drug boasts 97.5% response rate
November 15, 2016Manufacturing and Production, Medical Communications, Research and Development AbbVie, hepatitis C, pan-genotypic
AbbVie released details on their latest trials for their investigational, pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530). In an eight week …
Novartis reveals positive three-year efficacy data for psoriatic arthritis drug
November 15, 2016Manufacturing and Production, Research and Development Cosentyx, Novartis, psoriatic arthritis
Novartis has claimed that its Cosentyx (secukinumab) treatment is now the first approved fully human interleukin-17A (IL-17A) inhibitor to demonstrate …
Teva’s white elephant plant in Mexico inoperative
November 14, 2016Manufacturing and Production Mexico, Rimsa, Teva
The Teva-Rimsa debacle continues to rumble on, with Teva’s plant in Mexico not producing any drugs for market. The plant …
Allergan appoints Adriane M. Brown to board of directors
November 14, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan
Allergan announced that Adriana M. Brown will join its board of directors on February 2017. Adriana Brown is currently the …
Latest content
ESTEVE CDMO adds $17.5m to Illinois expansion
Brenntag and dsm-firmenich expand biopharma vitamin partnership
